Stockscreener 앱 받기
4.68
6.40%
-0.32
시간 외 거래:
4.36
-0.32
-6.84%
전일 마감가:
$5.00
열려 있는:
$5.09
하루 거래량:
40,746
Relative Volume:
2.56
시가총액:
$43.69M
수익:
-
순이익/손실:
$-37.72M
주가수익비율:
-0.6199
EPS:
-7.5501
순현금흐름:
$-52.35M
1주 성능:
-2.30%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$4.58
$5.09
1주일 범위
$4.415
$5.1512
52주 변동 폭
$4.4001
$6.625
Leonabio Inc Stock (LONA) Company Profile
명칭
Leonabio Inc
전화
(425) 620-8501
주소
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
4.68 | 46.68M | 0 | -37.72M | -52.35M | -7.5501 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-19 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2024-09-04 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-09-04 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | 개시 | Rodman & Renshaw | Buy |
| 2022-10-17 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | 개시 | Mizuho | Buy |
| 2022-06-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-06-23 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-05-10 | 개시 | BTIG Research | Buy |
| 2022-04-21 | 개시 | Berenberg | Buy |
| 2021-12-15 | 개시 | Goldman | Neutral |
| 2020-10-13 | 개시 | Goldman | Buy |
| 2020-10-13 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-13 | 개시 | Jefferies | Buy |
| 2020-10-13 | 개시 | Stifel | Buy |
모두보기
Leonabio Inc 주식(LONA)의 최신 뉴스
LeonaBio (ATHA) proxy asks investors to back warrant share issuances and 2026 equity plan - stocktitan.net
LeonaBio appoints Mark Kubik as chief business officer By Investing.com - Investing.com Nigeria
Leonabio, Inc. Announces the Appointment of Mark F. Kubik as Chief Business Officer - marketscreener.com
LeonaBio (LONA) Names Mark Kubik as New Chief Business Officer - GuruFocus
LeonaBio appoints Mark Kubik as chief business officer - Investing.com
LeonaBio, Inc. Appoints Mark F. Kubik as Chief Business Officer to Drive Business Development Strategy - Quiver Quantitative
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer - marketscreener.com
Biopharma deal veteran to drive LeonaBio’s Phase 3 breast cancer drug - Stock Titan
Leonabio Inc files for offering of up to 58.5 million shares of common stock by the selling stockholders - marketscreener.com
Leonabio Inc Files For Offering Of Up To 58.5 Million Shares Of Common Stock By The Selling Stockholders - TradingView
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker "LONA" - Investing News Network
Athira Pharma (ATHA) Options to Be Delisted on January 12th - GuruFocus
LONA Stock Price, News & Analysis - Stock Titan
Athira Pharma Rebrands as LeonaBio, Refocusing on Oncology - TipRanks
Athira Pharma announces name change to LeonaBio - TipRanks
Athira Pharma roars into the new year with rebrand to LeonaBio - Fierce Pharma
Athira Pharma changes name, ticker symbol - MSN
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy - Investing.com Nigeria
Athira Pharma rebrands as LeonaBio amid strategic pivot to cancer therapy By Investing.com - Investing.com South Africa
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance
New breast cancer drug moves into late testing with $236M funding deal - Stock Titan
Athira Pharma (NASDAQ: ATHA) posts $6.6M Q3 loss; ATH-1105 study shows favorable safety, CNS penetration - Stock Titan
Athira Pharma announces reverse stock split - marketscreener.com
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 - GlobeNewswire
Breakthrough ALS Drug ATH-1105 Achieves Key Safety Milestones, Targets Patient Trials Late 2025 - Stock Titan
Athira Pharma Slides As Insider Purchases Lose Another US$89k - simplywall.st
ATHA Stock Price, News & Analysis - stocktitan.net
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases - marketscreener.com
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology - marketscreener.com
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND - marketscreener.com
Athira Pharma, Inc. Plans to Further Extend the Current OLEX for the Phase 2/3 LIFT-AD and Phase 2 ACT-AD Trials - marketscreener.com
Athira Pharma Provides 2023 Pipeline Outlook - marketscreener.com
Goldman Sachs Adjusts Price Target for Athira Pharma to $3 From $11, Maintains Neutral Rating - marketscreener.com
Athira Pharma Reports First Quarter 2022 Financial Results and Provides Pipeline and Business Updates - marketscreener.com
Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth - simplywall.st
Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg.com
ATHAAthira Pharma, Inc. Latest Stock News & Market Updates - Stock Titan
Leonabio Inc (LONA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Leonabio Inc 주식 (LONA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| San Martin Javier | CHIEF MEDICAL OFFICER |
Jan 02 '26 |
Sale |
6.88 |
1,644 |
11,311 |
10,189 |
| Litton Mark James | President and CEO |
Dec 31 '25 |
Option Exercise |
0.00 |
10,834 |
0 |
43,414 |
| Litton Mark James | President and CEO |
Jan 02 '26 |
Sale |
6.88 |
2,586 |
17,792 |
40,828 |
| Renninger Robert | Chief Financial Officer |
Dec 31 '25 |
Option Exercise |
0.00 |
1,236 |
0 |
13,154 |
| Renninger Robert | Chief Financial Officer |
Jan 02 '26 |
Sale |
6.88 |
297 |
2,043 |
12,857 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
21,557 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
20,681 |
| Worthington Mark | General Counsel and CCO |
Dec 31 '25 |
Option Exercise |
0.00 |
3,667 |
0 |
14,854 |
| Worthington Mark | General Counsel and CCO |
Jan 02 '26 |
Sale |
6.88 |
876 |
6,027 |
13,978 |
| CHURCH KEVIN | CHIEF SCIENTIFIC OFFICER |
Jun 30 '25 |
Option Exercise |
0.00 |
36,666 |
0 |
177,427 |
1.24%
0.19%
자본화:
|
볼륨(24시간):